Drug & intervention

hydralazine

RxCUI 5470

Clinical trials14
Recruiting1
Related conditions15
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Hydralazine

Hydralazine, sold under the brand name Apresoline among others, is a medication used to treat high blood pressure and heart failure. This includes high blood pressure in pregnancy and very high blood pressure resulting in symptoms. It has been found to be particularly useful in heart failure, together with isosorbide dinitrate, for treatment of people of African descent. It is given by mouth or by injection into a vein. Effects usually begin around 15 minutes and last up to six hours. Common side effects include headache and fast heart rate. It is not recommended in people with coronary artery disease or in those with rheumatic heart disease that affects the mitral valve. In those with kidney disease a low dose is recommended. Hydralazine is in the vasodilator family of medications, so it is believed to work by causing the dilation of blood vessels. Hydralazine was discovered while scientists at Ciba were looking for a treatment for malaria. It was patented in 1949. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 109th most commonly prescribed medication in the United States, with more than 6 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

14 shown
Diuretics vs. Afterload Reduction for Treatment of HeartLogic AlertsNCT06218199 · 2021-07-08
RECRUITING
Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe PreeclampsiaNCT07572656 · 2024-05-01
COMPLETED
Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in PregnancyNCT04435210 · 2018-08-13
COMPLETED
Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency ProtocolsNCT02933593 · 2016-08-01
WITHDRAWN
Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) StudyNCT02343393 · 2015-01-01
UNKNOWN
Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart FailureNCT01822808 · 2013-01-01
UNKNOWN
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.NCT02050529 · 2012-10-01
COMPLETED
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of PregnancyNCT01538875 · 2012-07-01
COMPLETED
Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced HypertensionNCT00607477 · 2008-01-01
TERMINATED
Sildenafil and Exercise Capacity in HypertensionNCT00599235 · 2007-03-01
COMPLETED
Black Education and Treatment of Hypertension (BEAT HTN)NCT00661895 · 2005-08-01
COMPLETED
Hydralazine as Demethylating Agent in Breast CancerNCT00575978 · 2004-06-01
WITHDRAWN
Treatment of Supine Hypertension in Autonomic FailureNCT00223717 · 2001-01-01
COMPLETED
Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)NCT00000499 · 1980-09-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.